欧林生物 (688319.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

166.2x

Market Cap

CNY 11.28B

MomentumView details →

1D Return

−7.42%

YTD Return

—

RSI (14)

48.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

166.2x

Market Cap

CNY 11.28B

RSI (14)

48.7

MomentumView details →

1D Return

−7.42%

YTD Return

—

ProfitabilityView details →

Gross Margin

92.68%

Net Margin

7.30%

EBITDA Margin

9.00%

ROE (TTM)

6.07%

ROA (TTM)

2.80%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

+27.90%

EPS YoY

+42.83%

FCF YoY

+100.16%

Revenue CAGR 3Y

+8.75%

EPS CAGR 3Y

−5.76%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.07

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.35x

Current Ratio

1.36x

Quick Ratio

1.26x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

774.47M

Net Income (TTM)

56.52M

Op. CF (TTM)

103.57M

Next earningsOct 26, 2026 →

Latest newsMore news →

On August 31, 2026, ten A-share listed companies including Olymvax Biopharmaceuticals, Xiaocheng Technology, Hengyin Technology, Xinhongye, Feirongda, Ruison Technology, Weiteng Electric, Jinge New Materials, Baling Oriental, and Bestore disclosed plans to reduce their holdings, while ST Kaili and XCMG disclosed plans to increase holdings.4d ago

Olymvax Biopharmaceuticals director and deputy general manager Chen Aimin plans to reduce his shareholding in the company by up to 0.0338% of total shares.4d ago

Similar companies

Suzhou Ribo Life Science Co06938.HK Bio-Techne CorporationTECH Mabwell-b02493.HK 诺唯赞688105.SH HBM Holdings Limited02142.HK Axsome Therapeutics, Inc.AXSM Find similar companies →

Latest newsMore news →

On August 31, 2026, ten A-share listed companies including Olymvax Biopharmaceuticals, Xiaocheng Technology, Hengyin Technology, Xinhongye, Feirongda, Ruison Technology, Weiteng Electric, Jinge New Materials, Baling Oriental, and Bestore disclosed plans to reduce their holdings, while ST Kaili and XCMG disclosed plans to increase holdings.4d ago Olymvax Biopharmaceuticals director and deputy general manager Chen Aimin plans to reduce his shareholding in the company by up to 0.0338% of total shares.4d ago Olymvax Biopharmaceuticals reported a net loss of 32.8726 million yuan for the first half of 2026, turning from a profit of 13.1969 million yuan a year earlier, with revenue of 361 million yuan, up 18.14% year-on-year.18d ago